RESUMO
RATIONALE: Exercise intolerance limits the ability of patients with chronic obstructive pulmonary disease (COPD) to perform daily living activities. Noninvasive ventilation reduces dyspnea and improves exercise performance, but current systems are unsuitable for ambulatory use. OBJECTIVES: In patients with COPD experiencing exercise-induced desaturation, we evaluated improvements in exercise tolerance facilitated by a wearable, 1-lb, noninvasive open ventilation (NIOV) system featuring a nasal pillow interface during constant work rate (CWR) cycle ergometer exercise and associated effects on dyspnea, respiratory muscle activation, and pulmonary gas exchange efficiency. METHODS: Fifteen men with COPD (FEV1 = 32.2 ± 12.0% predicted; FEV1/FVC = 31.6 ± 7.1%; exercise oxygen saturation as measured by pulse oximetry [Spo2] = 86.5 ± 2.9%) participated. After incremental testing establishing peak work rate, subjects completed three visits in which they performed CWR exercise to tolerance at 80% peak work rate: (1) unencumbered breathing room air, (2) using NIOV+compressed air, (3) using NIOV+compressed O2, or (4) using O2 via nasal cannula. Assessments included exercise duration, surface inspiratory muscle EMG, Spo2, transcutaneous Pco2, and Borg dyspnea scores. MEASUREMENTS AND MAIN RESULTS: Exercise endurance was 17.6 ± 5.7 minutes using NIOV+O2, greatly prolonged compared with unencumbered (5.6 ± 1.9 min), nasal O2 (11.4 ± 6.8 min), and NIOV+Air (6.3 ± 4.1 min). Isotime Spo2 was higher and intercostal, scalene, and diaphragmatic EMG activity was reduced using NIOV+O2 compared with unencumbered, nasal O2, and NIOV+Air, signifying respiratory muscle unloading. Isotime dyspnea reduction correlated with isotime EMG reduction (r = 0.42, P = 0.0053). There were no significant differences in isotime VD/VT or transcutaneous Pco2 among treatments. CONCLUSIONS: NIOV+O2 yielded substantial exercise endurance improvements accompanied by respiratory muscle unloading and dyspnea reductions in patients with severe hypoxemic COPD.
Assuntos
Assistência Ambulatorial/métodos , Tolerância ao Exercício/fisiologia , Ventilação não Invasiva/instrumentação , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Respiração , Idoso , Desenho de Equipamento , Feminino , Humanos , Masculino , Doença Pulmonar Obstrutiva Crônica/terapia , Troca Gasosa Pulmonar , Testes de Função Respiratória , Músculos Respiratórios/fisiopatologiaRESUMO
BACKGROUND: This study assessed the clinical effects of a ventilatory assist (VA) device in addition to supplemental O2 (VA+O2) on exercise endurance in subjects with severe to very severe COPD managed with long-term oxygen therapy (LTOT). METHODS: This was a crossover clinical feasibility study of the effects of VA+O2 in subjects with severe to very severe COPD managed with LTOT (N = 15). At visit 1, physiologic measures were obtained, and subjects were tested on the cycle ergometer with VA. Peak work rate and flow for continuous supplemental O2/VA+O2 were established. At visit 2, subjects exercised at a constant work rate of 80% peak work rate to maximum endurance after allocation to VA+O2 or O2. Cardiorespiratory variables, work rate, and dyspnea were included to define potential clinical benefits of VA+O2. Data were analyzed using a linear mixed model. RESULTS: Fifteen subjects with COPD (mean ± SD, age 67.9 ± 9.0 y, FEV1 0.89 ± 0.35 observed) completed the study. Exercise duration in minutes was significantly longer with VA+O2 versus O2 (least squares mean [standard error], 12.0 [2.0] vs 6.2 [2.0], P = .01). VA+O2 versus O2 was also associated with significantly greater isotime improvements in Borg dyspnea scores (3.6 [0.5] vs 5.7 [0.5], P < .001), SpO2 (96.9 [0.9] vs 91.4 [0.9], P < .001), leg fatigue scores (3.8 [0.6] vs 5.2 [0.6], P = .008), and breathing frequency (22.8 [0.9] vs 25.8 [0.9] breaths/min, P = .01). There were no differences in heart rate. CONCLUSIONS: In symptomatic subjects with severe to very severe COPD, VA+O2 significantly increased exercise time and improved dyspnea, SpO2 , breathing frequency, and leg fatigue versus O2 alone.
RESUMO
This was a preliminary feasibility study to assess the pharmacokinetics and acute safety of a single dose of orally inhaled testosterone via the AERx system, a novel handheld aerosol delivery system in postmenopausal women. Twelve postmenopausal women stabilized on oral estrogen therapy were treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation. Plasma concentrations of sex steroids were measured between 1 and 360 minutes. Pulmonary and cardiovascular adverse events were monitored. Inhaled testosterone produced a dose-dependent increase in plasma total and free testosterone. At the highest dose (0.3 mg), total and free testosterone increased from baseline (mean +/- SD, 0.6 +/- 0.3 nmol/L, 2.5 +/- 1.0 pmol/L) to maximum levels of 62.6 +/- 20.4 nmol/L (total) and 168.2 +/- 50.2 pmol/L(free), occurring 1 to 2 minutes after dosing. A 2-compartment model best described the free and total testosterone pharmacokinetic profile. Dihydrotestosterone levels were higher than baseline at 60 minutes (P < .0002). Estradiol did not vary, but sex hormone binding globulin and albumin fell. There were no adverse events related to the treatment. Administration of inhaled testosterone is safe and achieves a supraphysiologic "pulse" kinetic profile of total and free testosterone with a rapid return to pretreatment levels.
Assuntos
Administração por Inalação , Pós-Menopausa/efeitos dos fármacos , Testosterona/farmacocinética , Área Sob a Curva , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Tosse/induzido quimicamente , Di-Hidrotestosterona/metabolismo , Relação Dose-Resposta a Droga , Feminino , Meia-Vida , Humanos , Pessoa de Meia-Idade , Nebulizadores e Vaporizadores , Seleção de Pacientes , Pós-Menopausa/fisiologia , Globulina de Ligação a Hormônio Sexual/metabolismo , Testosterona/administração & dosagem , Testosterona/metabolismo , Fatores de Tempo , Resultado do Tratamento , Capacidade Vital/efeitos dos fármacosRESUMO
BACKGROUND: The AERx Pain Management System (Aradigm Corporation, Hayward, CA) is a novel pulmonary delivery system for the systemic administration of morphine. The authors compared the relative analgesic efficacy and safety of the AERx Pain Management System with those of placebo and intravenous morphine in an orthopedic postsurgical pain model. METHODS: Eighty-nine male and female PS-1 to PS-3 patients underwent standardized bunionectomy surgery and received multiple doses of inhaled or intravenous placebo, inhaled morphine (one inhalation [2.2 mg] or three inhalations [6.6 mg]), or intravenous morphine (4 mg) in a blinded fashion. Open-label rescue morphine (2 mg) was also available as needed. Pain intensity, pain relief, and time to pain relief were measured after the first dose. Global evaluation, morphine consumption, vital signs, and adverse events were monitored for 8 h after treatment. Blinded study personnel performed all treatment administrations and pain assessments. RESULTS: Three inhalations of morphine and 4 mg intravenous morphine provided comparable single- and multiple-dose analgesia. One inhalation of morphine was statistically indistinguishable from placebo. Three inhalations of morphine and 4 mg intravenous morphine both consistently demonstrated significantly greater analgesic efficacy than did placebo and one inhalation of morphine. CONCLUSIONS: Comparable analgesic efficacy was demonstrated between a carefully matched dose of inhaled and intravenous morphine in a postsurgical pain model.